avatar
GSK怎么了?# Stock
N*d
1
女CEO 惹的祸?
avatar
d*l
2
再等等,有好的entry point就杀进去
avatar
N*d
3
女CEO果然不作不死
GlaxoSmithKline's (GSK) new chief executive will narrow the focus of its
drug research by eliminating more than 30 drug projects, Reuters said.
CEO Emma Walmsley, who took over in April, said GSK will allocate 80% of its
R&D budget to respiratory and HIV/infectious diseases, along with two other
potential areas of oncology and immuno-inflammation. A total of 13 clinical
and around 20 pre-clinical programs will be stopped, partnered or divested,
the report said, and the group is considering options for its rare diseases
unit after a strategic review.
相关阅读
logo
联系我们隐私协议©2024 redian.news
Redian新闻
Redian.news刊载任何文章,不代表同意其说法或描述,仅为提供更多信息,也不构成任何建议。文章信息的合法性及真实性由其作者负责,与Redian.news及其运营公司无关。欢迎投稿,如发现稿件侵权,或作者不愿在本网发表文章,请版权拥有者通知本网处理。